Skip to main content
SpringerLink
Log in

Atezolizumab + bevacizumab unlikely cost-effective first-line option in HCC

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Su D, et al. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Network Open : 24 Feb 2021. Available from: URL: http;//dx.doi.org/10.1001/jamanetworkopen.2021.0037

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab + bevacizumab unlikely cost-effective first-line option in HCC. PharmacoEcon Outcomes News 873, 2 (2021). https://doi.org/10.1007/s40274-021-7511-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7511-8

Search

Navigation